|
1
|
Ferlay J, Steliarova-Foucher E,
Lortet-Tieulent J, Rosso S, Coebergh JW, Comber H, Forman D and
Bray F: Cancer incidence and mortality patterns in Europe:
Estimates for 40 countries in 2012. Eur J Cancer. 49:1374–1403.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2015. CA Cancer J Clin. 65:5–29. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Wang BY, Huang JY, Cheng CY, Lin CH, Ko J
and Liaw YP: Lung cancer and prognosis in Taiwan: A
population-based cancer registry. J Thorac Oncol. 8:1128–1135.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Douillard JY, Rosell R, De Lena M,
Carpagnano F, Ramlau R, Gonzáles-Larriba JL, Grodzki T, Pereira JR,
Le Groumellec A, Lorusso V, et al: Adjuvant vinorelbine plus
cisplatin versus observation in patients with completely resected
stage IB-IIIA non-small-cell lung cancer (Adjuvant Navelbine
International Trialist Association [ANITA]): A randomised
controlled trial. Lancet Oncol. 7:719–727. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Gilligan D, Nicolson M, Smith I, Groen H,
Dalesio O, Goldstraw P, Hatton M, Hopwood P, Manegold C, Schramel
F, et al: Preoperative chemotherapy in patients with resectable
non-small cell lung cancer: Results of the MRC LU22/NVALT 2/EORTC
08012 multicentre randomised trial and update of systematic review.
Lancet. 369:1929–1937. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Lim E, Harris G, Patel A, Adachi I,
Edmonds L and Song F: Preoperative versus postoperative
chemotherapy in patients with resectable non-small cell lung
cancer: Systematic review and indirect comparison meta-analysis of
randomized trials. J Thorac Oncol. 4:1380–1388. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
NSCLC Meta-Analyses Collaborative Group, :
Chemotherapy in addition to supportive care improves survival in
advanced non-small-cell lung cancer: A systematic review and
meta-analysis of individual patient data from 16 randomized
controlled trials. J Clin Oncol. 26:4617–4625. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Delbaldo C, Michiels S, Syz N, Soria JC,
Le Chevalier T and Pignon JP: Benefits of adding a drug to a
single-agent or a 2-agent chemotherapy regimen in advanced
non-small-cell lung cancer: A meta-analysis. JAMA. 292:470–484.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Li M, Zhang Q, Fu P, Li P, Peng A, Zhang
G, Song X, Tan M, Li X, Liu Y, et al: Pemetrexed plus platinum as
the first-line treatment option for advanced non-small cell lung
cancer: A meta-analysis of randomized controlled trials. PLoS One.
7:e372292012. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Effects of vinorelbine on quality of life
and survival of elderly patients with advanced non-small-cell lung
cancer. The Elderly Lung Cancer Vinorelbine Italian Study Group. J
Natl Cancer Inst. 91:66–72. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Maemondo M, Inoue A, Kobayashi K, Sugawara
S, Oizumi S, Isobe H, Gemma A, Harada M, Yoshizawa H, Kinoshita I,
et al: Gefitinib or chemotherapy for non-small-cell lung cancer
with mutated EGFR. N Engl J Med. 362:2380–2388. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Han JY, Park K, Kim SW, Lee DH, Kim HY,
Kim HT, Ahn MJ, Yun T, Ahn JS, Suh C, et al: First-SIGNAL:
First-line single-agent iressa versus gemcitabine and cisplatin
trial in never-smokers with adenocarcinoma of the lung. J Clin
Oncol. 30:1122–1128. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Carter BW, Lichtenberger JP III,
Benveniste MK, de Groot PM, Wu CC, Erasmus JJ and Truong MT:
Revisions to the TNM staging of lung cancer: Rationale,
significance, and clinical application. Radiographics. 38:374–391.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
http://regulation.cde.org.tw/data/downloadfile.php?sid=910
|
|
15
|
Skrbo A, Begovic B and Skrbo S:
Classification of drugs using the ATC system (Anatomic,
Therapeutic, Chemical Classification) and the latest changes. Med
Arh. 58 (1 Suppl 2):S138–S141. 2004.(In Bosnian).
|
|
16
|
Liang YH, Shao YY, Liao BC, Lee HS, Yang
JC, Chen HM, Chiang CJ, Cheng AL and Lai MS: Cytotoxic chemotherapy
as first-line therapy for advanced non-small-cell lung cancer in
Taiwan: Daily practice. J Cancer. 7:1515–1523. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Masters GA, Temin S, Azzoli CG, et al:
Systemic therapy for stage IV non-small-cell lung cancer: American
Society of Clinical Oncology Clinical Practice Guideline Update. J
Clin Oncol. 33:3488–3515. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
D'Addario G, Pintilie M, Leighl NB, Feld
R, Cerny T and Shepherd FA: Platinum-based versus
non-platinum-based chemotherapy in advanced non-small-cell lung
cancer: A meta-analysis of the published literature. J Clin Oncol.
23:2926–2936. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Kim ST, Uhm JE, Lee J, Sun JM, Sohn I, Kim
SW, Jung SH, Park YH, Ahn JS, Park K and Ahn MJ: Randomized phase
II study of gefitinib versus erlotinib in patients with advanced
non-small cell lung cancer who failed previous chemotherapy. Lung
Cancer. 75:82–88. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Chang CH, Lee CH, Ko JC, Chang LY, Lee MC,
Wang JY and Yu CJ: Gefitinib or erlotinib in previously treated
non-small-cell lung cancer patients: A cohort study in Taiwan.
Cancer Med. 6:1563–1572. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Kim ES, Hirsh V, Mok T, Socinski MA,
Gervais R, Wu YL, Li LY, Watkins CL, Sellers MV, Lowe ES, et al:
Gefitinib versus docetaxel in previously treated non-small-cell
lung cancer (INTEREST): A randomised phase III trial. Lancet.
372:1809–1818. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Ciuleanu T, Stelmakh L, Cicenas S,
Miliauskas S, Grigorescu AC, Hillenbach C, Johannsdottir HK,
Klughammer B and Gonzalez EE: Efficacy and safety of erlotinib
versus chemotherapy in second-line treatment of patients with
advanced, non-small-cell lung cancer with poor prognosis (TITAN): A
randomised multicentre, open-label, phase 3 study. Lancet Oncol.
13:300–308. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Garassino MC, Martelli O, Broggini M,
Farina G, Veronese S, Rulli E, Bianchi F, Bettini A, Longo F,
Moscetti L, et al: Erlotinib versus docetaxel as second-line
treatment of patients with advanced non-small-cell lung cancer and
wild-type EGFR tumours (TAILOR): A randomised controlled trial.
Lancet Oncol. 14:981–988. 2013. View Article : Google Scholar : PubMed/NCBI
|
